SCHEMBL6793349

SCHEMBL6793349

CSNC(=O)Cc1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.59
KMT2A Q03164 1/20 0.59
HDAC8 Q9BY41 1/20 0.59
HDAC6 Q9UBN7 1/20 0.59
EPHX2 P34913 1/20 0.55
HPGD P15428 3/20 0.51
ALDH1A1 P00352 5/20 0.50
CNR2 P34972 3/20 0.50
CES2 O00748 1/20 0.50
CES1 P23141 1/20 0.50
AKR1B1 P15121 1/20 0.50
LMNA P02545 2/20 0.49
GAA P10253 2/20 0.49
POLB P06746 1/20 0.49
KDM4E B2RXH2 1/20 0.49
CCNE1 P24864 1/20 0.48
CDK2 P24941 1/20 0.48
CDK5 Q00535 1/20 0.48
TSHR P16473 1/20 0.48
SMN1; SMN2 Q16637 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19523027 0.81 ALDH1A1 (0.56) MEN1KMT2AALDH1A1CNR2LMNA
SCHEMBL21665925 0.81 KMT2A (0.54) MEN1KMT2ALMNAKDM4ESMN1; SMN2
SCHEMBL28005485 0.81 MEN1 (0.55) MEN1KMT2AHDAC8HDAC6EPHX2
SCHEMBL27992771 0.81 ALDH1A1 (0.56) MEN1KMT2AHDAC8HDAC6EPHX2
SCHEMBL18896342 0.80 KMT2A (0.59) MEN1KMT2AHDAC8HDAC6EPHX2
SCHEMBL29156061 0.79 MEN1 (0.53) MEN1KMT2AHDAC8HDAC6EPHX2
SCHEMBL13946104 0.78 MEN1 (0.52) MEN1KMT2AHDAC8HDAC6EPHX2
SCHEMBL27059184 0.78 HPGD (0.46) HPGDLMNATSHR
SCHEMBL60236 0.77 MEN1 (0.65) MEN1KMT2AHDAC8HDAC6EPHX2
SCHEMBL699925 0.76 MEN1 (0.71) MEN1KMT2AHDAC8HDAC6EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230348369-A1 NAMPT MODULATORS CYTOKINETICS, INC. 2023-11-02 US disclosed
US-6743794-B2 MULTIDRUG RESISTANCE PROTEIN; CANCER; 3-(9-CHLORO-3-METHYL-4-OXO-5H-ISOXAZOLO(4,3-C)QUINOLIN-5-YL)) CYCLOHEXYL)-2-PIPERIDYLACETAMIDE ELI LILLY AND COMPANY 2004-06-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348369-A1 NAMPT MODULATORS NAMPT, NNT, NAPRT MEN1 110/4885KMT2A 1973/4885HDAC8 413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.